Bacon CM

Barnard A

Blain AE

Bomken S

Burke GAA

Crossland RE

De Zordi J

Enshaei A

Erhorn A

Harding F

Harrison CJ

Newman AM

Rand V

Taj M

Televantou D

Turner SD

Wilkinson S

Wood KM

Zaka M

Zhou P

\ua9 2021, The Author(s). Children with B-cell non-Hodgkin lymphoma (B-NHL) have an excellent chance of survival, however, current clinical risk stratification places as many as half of patients in a high-risk group receiving very intensive chemo-immunotherapy. TP53 alterations are associated with adverse outcome in many malignancies; however, whilst common in paediatric B-NHL, their utility as a risk classifier is unknown. We evaluated the clinical significance of TP53 abnormalities (mutations, deletion and/or copy number neutral loss of heterozygosity) in a large UK paediatric B-NHL cohort and determined their impact on survival. TP53 abnormalities were present in 54.7% of cases and were independently associated with a significantly inferior survival compared to those without a TP53 abnormality (PFS 70.0% vs 100%, p &lt; 0.001, OS 78.0% vs 100%, p = 0.002). Moreover, amongst patients clinically defined as high-risk (stage III with high LDH or stage IV), those without a TP53 abnormality have superior survival compared to those with TP53 abnormalities (PFS 100% vs 55.6%, p = 0.005, OS 100% vs 66.7%, p = 0.019). Biallelic TP53 abnormalities were either maintained from the presentation or acquired at progression in all paired diagnosis/progression Burkitt lymphoma cases. TP53 abnormalities thus define clinical risk groups within paediatric B-NHL and offer a novel molecular risk stratifier, allowing more personalised treatment protocols

Newcastle University E-Prints

English

Genomic abnormalities of <em>TP53</em> define distinct risk groups of paediatric B-cell non-Hodgkin lymphoma

Genomic abnormalities of <em>TP53</em> define distinct risk groups of paediatric B-cell non-Hodgkin lymphoma

Abstract

Similar works

Full text

Available Versions

Newcastle University E-Prints